Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or LenalidomideReportar como inadecuado




Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Case Reports in HematologyVolume 2013 2013, Article ID 651902, 5 pages

Case ReportHematology & Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Iwate 020-8505, Japan

Received 25 January 2013; Accepted 3 March 2013

Academic Editors: E. Arellano-Rodrigo, K. Konstantopoulos, M.-C. Kyrtsonis, R. Lowenthal, and Y. Matsukawa

Copyright © 2013 Shigeki Ito et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Novel agents such as thalidomide, lenalidomide, and bortezomib have been shown to possess potent activity against multiple myeloma. However, the treatment strategy for patients who acquired resistance to these agents has not been established. In addition to switching drug classes, intensified treatment strategy, including increase in the dosage of current agents and addition of other agents, may be considered for these patients. We here describe 2 myeloma patients with acquired resistance to bortezomib or lenalidomide, in whom add-on therapy with low-dose cyclophosphamide was effective and tolerable. These cases suggest that add-on therapy with cyclophosphamide is one of the treatment options to overcome resistance to novel agents in patients with multiple myeloma. A larger prospective study is needed to clarify the efficacy and safety of this strategy for novel agent-resistant multiple myeloma.





Autor: Shigeki Ito, Tatsuo Oyake, Kazunori Murai, and Yoji Ishida

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados